Beijing Foyou Pharma (SHA:601089) received approval from China's drug administrator for the marketing application of its pinaverium bromide active pharmaceutical ingredient.
The approval is valid until January 2031, according to a Thursday filing with the Shanghai bourse.
Pinaverium bromide is used for the symptomatic treatment of pain related to intestinal and biliary functional disorders.
Shares of the pharmaceutical company closed 4% higher Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.